Market Overview

UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT on HeartWare International

Share:

In a report published Monday, Goldman Sachs Group reiterated its Neutral rating on HeartWare International (NASDAQ: HTWR), but lowered its price target from $86.00 to $84.00.

Goldman Sachs noted, “Following a detailed review of the left ventricular assist device market, we maintain our Neutral rating on shares of HTWR. We reduce our 2013-2016 revenue estimates to reflect a slower launch of the company's recent US approval for the HVAD device. Longer-term, we continue to have a bullish view on LVADs in general (we model +19% growth through 2016E) and see HeartWare as an attractive fundamental and strategic asset. However, over the near-term we think expectations for the company's US product launch need to be reset. We think HTWR will remain range-bound, as we would also not expect to see material downside unless we developed strong conviction that its long-term growth prospects (primarily approval for Destination Therapy) are in jeopardy.”

HeartWare International closed on Friday at $82.31.

Latest Ratings for HTWR

DateFirmActionFromTo
Aug 2016TerminatesNeutral
Jul 2016DowngradesOutperformMarket Perform
Jun 2016DowngradesBuyNeutral

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (HTWR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WUBABOCOM InternationalDowngrades
DLTROTR GlobalUpgrades
ARCCCompass PointDowngrades
GTYHCitiInitiates Coverage On7.0
NKEGuggenheimMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

STEC CEO, Founder Make Open-Market Purchases of Stock

UPDATE: Goldman Sachs Upgrades Thoratec Corporation to CL-Buy, Raises PT